Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $333.14 billion. The enterprise value is $345.00 billion.
| Market Cap | 333.14B |
| Enterprise Value | 345.00B |
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 21.76 and the forward PE ratio is 17.58.
| PE Ratio | 21.76 |
| Forward PE | 17.58 |
| PS Ratio | 7.58 |
| Forward PS | 1.29 |
| PB Ratio | 16.60 |
| P/TBV Ratio | 78.85 |
| P/FCF Ratio | 27.36 |
| P/OCF Ratio | 17.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.33, with an EV/FCF ratio of 28.34.
| EV / Earnings | 22.76 |
| EV / Sales | 7.85 |
| EV / EBITDA | 15.33 |
| EV / EBIT | 16.22 |
| EV / FCF | 28.34 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.86.
| Current Ratio | 0.74 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.41 |
| Interest Coverage | 41.95 |
Financial Efficiency
Return on equity (ROE) is 88.12% and return on invested capital (ROIC) is 47.91%.
| Return on Equity (ROE) | 88.12% |
| Return on Assets (ROA) | 23.29% |
| Return on Invested Capital (ROIC) | 47.91% |
| Return on Capital Employed (ROCE) | 58.02% |
| Revenue Per Employee | $567,845 |
| Profits Per Employee | $195,965 |
| Employee Count | 77,349 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.01 billion in taxes.
| Income Tax | 4.01B |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has decreased by -47.28% in the last 52 weeks. The beta is 0.22, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -47.28% |
| 50-Day Moving Average | 68.02 |
| 200-Day Moving Average | 91.77 |
| Relative Strength Index (RSI) | 52.86 |
| Average Volume (20 Days) | 9,006,838 |
Short Selling Information
The latest short interest is 33.67 million, so 1.00% of the outstanding shares have been sold short.
| Short Interest | 33.67M |
| Short Previous Month | 25.12M |
| Short % of Shares Out | 1.00% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.98 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $43.92 billion and earned $15.16 billion in profits. Earnings per share was $3.40.
| Revenue | 43.92B |
| Gross Profit | 37.18B |
| Operating Income | 21.27B |
| Pretax Income | n/a |
| Net Income | 15.16B |
| EBITDA | 22.50B |
| EBIT | 21.27B |
| Earnings Per Share (EPS) | $3.40 |
Balance Sheet
The company has $6.02 billion in cash and $17.20 billion in debt, giving a net cash position of -$11.18 billion or -$2.52 per share.
| Cash & Cash Equivalents | 6.02B |
| Total Debt | 17.20B |
| Net Cash | -11.18B |
| Net Cash Per Share | -$2.52 |
| Equity (Book Value) | 20.07B |
| Book Value Per Share | 4.52 |
| Working Capital | -8.94B |
Cash Flow
In the last 12 months, operating cash flow was $19.02 billion and capital expenditures -$7.55 billion, giving a free cash flow of $12.18 billion.
| Operating Cash Flow | 19.02B |
| Capital Expenditures | -7.55B |
| Free Cash Flow | 12.18B |
| FCF Per Share | $2.74 |
Margins
Gross margin is 84.65%, with operating and profit margins of 48.43% and 34.51%.
| Gross Margin | 84.65% |
| Operating Margin | 48.43% |
| Pretax Margin | 43.65% |
| Profit Margin | 34.51% |
| EBITDA Margin | 51.23% |
| EBIT Margin | 48.43% |
| FCF Margin | 27.72% |
Dividends & Yields
This stock pays an annual dividend of $1.61, which amounts to a dividend yield of 2.18%.
| Dividend Per Share | $1.61 |
| Dividend Yield | 2.18% |
| Dividend Growth (YoY) | 17.49% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 47.38% |
| Buyback Yield | 0.61% |
| Shareholder Yield | 2.78% |
| Earnings Yield | 4.55% |
| FCF Yield | 3.65% |
Analyst Forecast
The average price target for Novo Nordisk is $112.00, which is 51.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $112.00 |
| Price Target Difference | 51.33% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 11.79% |
| EPS Growth Forecast (5Y) | 14.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 7.88 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.88 |
| Piotroski F-Score | 5 |